Abstract:DddA-derived cytosine base editors (DdCBEs) enable the targeted introduction of C·G-to-T·A conversions in mitochondrial DNA (mtDNA). DdCBEs are often deployed as pairs, with each arm comprised of a transcription activator-like effector (TALE), a split double-stranded DNA deaminase half, and a uracil glycosylase inhibitor. This pioneering technology has helped improve our understanding of cellular processes involving mtDNA and has paved the way for the development of models and therapies for genetic disorders caused by pathogenic mtDNA variants. Nonetheless, given the intrinsic properties of TALE proteins, several target sites in human mtDNA remain out of reach to DdCBEs and other TALE-based technologies. Specifically, due to the conventional requirement for a thymine immediately upstream of the TALE target sequences (i.e., the 5′-T constraint), over 150 loci in the human mitochondrial genome are presumed to be inaccessible to DdCBEs. Previous attempts at circumventing this constraint, either by developing monomeric DdCBEs or utilizing DNA-binding domains alternative to TALEs, have resulted in suboptimal specificity profiles with reduced therapeutic potential. Here, aiming to challenge and elucidate the relevance of the 5′-T constraint in the context of DdCBE-mediated mtDNA editing, and to expand the range of motifs that are editable by this technology, we generated αDdCBEs that contain modified TALE proteins engineered to recognize all 5′ bases. Notably, 5′-T-noncompliant, canonical DdCBEs efficiently edited mtDNA at diverse loci. However, DdCBEs were frequently outperformed by αDdCBEs, which consistently displayed significant improvements in activity and specificity, regardless of the 5′-most bases of their TALE binding sites. Furthermore, we showed that αDdCBEs are compatible with DddAtox and its derivatives DddA6, and DddA11, and we validated TALE shifting with αDdCBEs as an effective approach to optimize base editing outcomes at a single target site. Overall, αDdCBEs enable efficient, specific, and unconstrained mitochondrial base editing.

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery

DdCBE Mediates Efficient and Inheritable Modifications in Mouse Mitochondrial Genome.

Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Unconstrained Precision Mitochondrial Genome Editing with αDdCBEs

Engineered mitochondrial A-to-G editors with enhanced efficiency and targeting scope

Enhanced C‐To‐T and A‐To‐G Base Editing in Mitochondrial DNA with Engineered DdCBE and TALED

Tools for editing the mammalian mitochondrial genome

Research Progress in Mitochondrial Gene Editing Technology.

Strand-selective base editing of human mitochondrial DNA using mitoBEs

Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors

New potentials of mitochondrial DNA editing

Harnessing accurate mitochondrial DNA base editing mediated by DdCBEs in a predictable manner

A DddA ortholog-based and transactivator-assisted nuclear and mitochondrial cytosine base editors with expanded target compatibility

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

Enzymatic tools for mitochondrial genome manipulation

Development of mitochondrial gene-editing strategies and their potential applications in mitochondrial hereditary diseases: a review

Secondary Follicles Enable Efficient Germline Mtdna Base Editing at Hard-to-edit Site

A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts